Skip to main content
SpringerLink
Log in

Genetics of Lung Cancer: Current Thinking on Genetic Predisposition to the Disease and Response to Treatment

  • Chapter
Tumors of the Chest

  • 829 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 179.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Doll R, Peto J. The cause of cancer. London, Oxford University Press, London, 1981; p 1221.

    Google Scholar 

  2. Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. BMJ 2000; 321:323.

    Article  PubMed  CAS  Google Scholar 

  3. Colby TV, Wistuba, II, Gazdar A. Precursors to pulmonary neoplasia. Adv Anat Pathol 1998; 5:205.

    PubMed  CAS  Google Scholar 

  4. Sekido Y, Fong KM, Minna JD. Progress in understanding the molecular pathogenesis of human lung cancer. Biochem Biophys Acta 1998; 1378: F21.

    PubMed  CAS  Google Scholar 

  5. Osada H, Takahashi T. Genetic alterations of multiple tumor suppressors and oncogenes in the carcinogenesis and progression of lung cancer. Oncogene 2002; 21:7421.

    Article  PubMed  CAS  Google Scholar 

  6. Wistuba II, Mao L, Gazdar AF. Smoking molecular damage in bronchial epithelium. Oncogene 2002;21(48):7298.

    Article  PubMed  CAS  Google Scholar 

  7. Lee PN. Epidemiological Studies relating family history of lung cancer to risk of the disease. Indoor Environ 1993; 2:129.

    Google Scholar 

  8. Houlston RS, Peto J. Genetics of common cancers. In: Eeles RA, Ponder B, Easton DE, Horwich A (eds) Inherited Predisposition to Cancer. Chapman Hall, New York, 1996; p 208.

    Google Scholar 

  9. Tokuhata GK, Lilienfeld AM. Familial aggregation of lung cancer in humans. J Natl Cancer Inst 1963; 30:289.

    PubMed  CAS  Google Scholar 

  10. Schwartz AG, Yang P, Swanson GM. Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol 1996; 144:554.

    PubMed  CAS  Google Scholar 

  11. Wang TJ, Zhou BS, Shi JP. Lung cancer in nonsmoking Chinese women: a case-control study. Lung Cancer 1996; 14Suppl 1: S93.

    Article  PubMed  Google Scholar 

  12. Wu AH, Fontham ET, Reynolds P, et al. Family history of cancer and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1996; 143:535.

    PubMed  CAS  Google Scholar 

  13. Mayne ST, Buenconsejo J, Janerich DT. Familial cancer history and lung cancer risk in United States nonsmoking men and women. Cancer Epidemiol Biomarkers Prev 1999; 8:1065.

    PubMed  CAS  Google Scholar 

  14. Braun MM, Caporaso NE, Page WF, Hoover RN. Genetic component of lung cancer: cohort study of twins. Lancet 1994; 344:440.

    Article  PubMed  CAS  Google Scholar 

  15. Braun MM, Caporaso NE, Page WF, Hoover, RN. A cohort study of twins and cancer. Cancer Epidemiol Biomarkers Prev 1995; 4:469.

    PubMed  CAS  Google Scholar 

  16. Lichtenstein P, Holm NV, Verkasalo PK, et al. Environ mental and heritable factors in the causation of cancer — analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343:78.

    Article  PubMed  CAS  Google Scholar 

  17. Risch A, Wikman H, Thiel S, et al. Glutathione-S-transferase Ml, M3, Tl and P1 polymorphisms and susceptibility to non-small-cell lung cancer subtypes and hamartomas. Pharmacogenetics 2001; 11:757.

    Article  PubMed  CAS  Google Scholar 

  18. Goldgar DE, Easton DF, Cannon-Albright LA, Skolnick MH. Systematic population-based assessment of cancer risk in first-degree relatives of cancer probands. J Natl Cancer Inst 1994; 86:1600.

    PubMed  CAS  Google Scholar 

  19. Hwang SJ, Cheng LS, Lozano G, Amos CI, Gu, X, Strong LC. Lung cancer risk in germline p53 mutation carriers: association between an inherited cancer predisposition, cigarette smoking, and cancer risk. Hum Genet 2003; 113:238.

    Article  PubMed  CAS  Google Scholar 

  20. Sanders BM., Jay M, Draper GJ, Roberts EM. Non-ocular cancer in relatives of retinoblastoma patients. Br J Cancer 1989; 60:358.

    PubMed  CAS  Google Scholar 

  21. Swift M, Chase C. Cancer in families with xeroderma pigmentosum. J Natl Cancer Inst 1979; 62:1415.

    PubMed  CAS  Google Scholar 

  22. Takemiya M, Shiraishi S, Teramoto T, Miki Y. Bloom’s syndrome with porokeratosis of Mibelli and multiple cancers of the skin, lung and colon. Clin Genet 1987; 31:35.

    Article  PubMed  CAS  Google Scholar 

  23. Yamanaka A, Hirai T, Ohtake Y, Kitagawa M. Lung cancer associated with Werner’s syndrome: a case report and review of the literature. Jpn J Clin Oncol 1997; 27:415.

    Article  PubMed  CAS  Google Scholar 

  24. Sellers TA, Chen PL, Potter JD, Bailey-Wilson JE, Rothschild H, Elston RC. Segregation analysis of smoking-associated malignancies: evidence for Mendelian inheritance. Am J Med Genet 1994; 52:308.

    Article  PubMed  CAS  Google Scholar 

  25. International Agency for Research on Cancer. Tobacco smoke and involuntary smoking. IARC Monographs on the evaluation of carcinogenic risks to humans 2002; p 83.

    Google Scholar 

  26. Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 2003; 3:733.

    Article  PubMed  CAS  Google Scholar 

  27. Pryor WA, Stone K. Oxidants in cigarette smoke. Radicals, hydrogen peroxide, peroxynitrate, and peroxynitrite. Ann N Y Acad Sci 1993; 686:27.

    Google Scholar 

  28. Phillips, DH. The formation of DNA adducts. In: Alison MR (ed) The Cancer Handbook. Nature Publishing Group, London, 2002; p 293.

    Google Scholar 

  29. Siddik ZH. Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumor platinum based drugs. In: Alison MR (ed) The Cancer Handbook. Nature Publishing Group, London, 2002; 1295.

    Google Scholar 

  30. Sancar A. DNA repair in humans. Annu Rev Genet 1995; 29:69.

    Article  PubMed  CAS  Google Scholar 

  31. Hoeijmakers JH. Human nucleotide excision repair syndromes: molecular clues to unexpected intricacies. Eur J Cancer 1994; 30A:1912.

    Article  PubMed  CAS  Google Scholar 

  32. Huang JC, Hsu DS, Kazantsev A, Sancar A. Substrate spectrum of human excinuclease: repair of abasic sites, methylated bases, mismatches, and bulky adducts. Proc Natl Acad Sci U S A 1994; 91:12213.

    Article  PubMed  CAS  Google Scholar 

  33. Wilson MD, Ruttan CC, Koop BF, Glickman BW ERCC1: a comparative genomic perspective. Environ Mol Mutagen 2001; 38:209.

    Article  PubMed  CAS  Google Scholar 

  34. Wei Q, Cheng L, Hong WK, Spitz MR. Reduced DNA repair capacity in lung cancer patients. Cancer Res 1996; 56:4103.

    PubMed  CAS  Google Scholar 

  35. Cheng L, Spitz MR, Hong WK, Wei Q. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 2000; 21:1527.

    Article  PubMed  CAS  Google Scholar 

  36. Martoni A, Marino A, Sperandi F, et al. Multicentre randomised phase III study comparing the same dose and schedule of cisplatin plus the same schedule of vinorelbine or gemcitabine in advanced non-small cell lung cancer. Eur J Cancer 2005; 41:81.

    Article  PubMed  CAS  Google Scholar 

  37. Schiller J, Harrington D, Belani PC, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 2002; 346:92.

    Article  PubMed  CAS  Google Scholar 

  38. Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62:4899.

    PubMed  CAS  Google Scholar 

  39. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8:2286.

    PubMed  CAS  Google Scholar 

  40. Sturgis EM, Dahlstrom KR, Spitz MR, Wei Q. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002; 128:1084.

    PubMed  Google Scholar 

  41. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann Oncol 2004; 15:1194.

    Article  PubMed  CAS  Google Scholar 

  42. Ryu JS, Hong YC, Han HS, et al. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 2004; 44:311.

    Article  PubMed  Google Scholar 

  43. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10:4939.

    Article  PubMed  CAS  Google Scholar 

  44. Weber CA, Salazar EP, Stewart SA, Thompson LH. ERCC2: cDNA cloning and molecular characterization of a human nucleotide excision repair gene with high homology to yeast RAD3. EMBO J 1990; 9:1437.

    PubMed  CAS  Google Scholar 

  45. Schaeffer L, Moncollin V, Roy R, et al. The ERCC2/DNA repair protein is associated with the class II BTF2/TFIIH transcription factor. EMBO J 1994; 13:2388.

    PubMed  CAS  Google Scholar 

  46. Friedberg EC. DNA damage and repair. Nature 2003; 421:436.

    Article  PubMed  CAS  Google Scholar 

  47. Hu Z, Wei Q, Wang X, Shen H. DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis. Lung Cancer 2004; 46:1.

    Article  PubMed  CAS  Google Scholar 

  48. Benhamou S, Sarasin, A. ERCC2/XPD gene polymorphisms and lung cancer: a huge review. Am J Epidemiol 2005; 161:1.

    Article  PubMed  Google Scholar 

  49. Camps C, Sarries C, Roig B, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 2003; 4:237.

    Article  PubMed  CAS  Google Scholar 

  50. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22:2594.

    Article  PubMed  CAS  Google Scholar 

  51. Rosell R, Taron M, Camps C, Lopez-Vivanco G. Influence of genetic markers on survival in non-small cell lung cancer. Drugs Today (Barc) 2003; 39:775.

    Article  CAS  Google Scholar 

  52. Lemmon MA, Schlessinger J. Regulation of signal transduction and signal diversity by receptor oligomerization. Trends Biochem Sci 1994; 19:459.

    Article  PubMed  CAS  Google Scholar 

  53. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 2000; 77:25.

    Article  PubMed  CAS  Google Scholar 

  54. Jones JT, Akita RW, Sliwkowski MX. Binding specificities and affinities of egf domains for ErbB receptors. FEBS Lett 1999; 447:227.

    Article  PubMed  CAS  Google Scholar 

  55. Wells A. EGF receptor. Int J Biochem Cell Biol 1999; 31:637.

    Article  PubMed  CAS  Google Scholar 

  56. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100:57.

    Article  PubMed  CAS  Google Scholar 

  57. Arteaga CL. ErbB-targeted therapeutic approaches in human cancer. Exp Cell Res 2003; 284:122.

    Article  PubMed  CAS  Google Scholar 

  58. Weinstein-Oppenheimer CR, Blalock WL, Steelman LS, Chang F, McCubrey JA. The Raf signal transduction cascade as a target for chemotherapeutic intervention in growth factor-responsive tumors. Pharmacol Ther 2000; 88:229.

    Article  PubMed  CAS  Google Scholar 

  59. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002; 2:489.

    Article  PubMed  CAS  Google Scholar 

  60. Wakeling AE, Guy SP, Woodburn JR, Ashton SE, Curry BJ, Barker AJ, Gibson KH. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62:5749.

    PubMed  CAS  Google Scholar 

  61. Ciardiello F, Caputo R, Bianco R, et al. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 2000; 6:2053.

    PubMed  CAS  Google Scholar 

  62. Sirotnak FM, Zakowski, MF, Miller VA, Scher HI, Kris MG. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000; 6:4885.

    PubMed  CAS  Google Scholar 

  63. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2000; 20:4292.

    Article  Google Scholar 

  64. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: re sults of a phase I trial. J Clin Oncol 2002; 20:3815.

    Article  PubMed  CAS  Google Scholar 

  65. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 1. J Clin Oncol 2004; 22:777.

    Article  PubMed  CAS  Google Scholar 

  66. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004; 22:785.

    Article  PubMed  CAS  Google Scholar 

  67. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 2003; 21:2237.

    Article  PubMed  CAS  Google Scholar 

  68. Kris MG, Natale, RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290:2149.

    Article  PubMed  CAS  Google Scholar 

  69. Shepherd FA, Pereira J, Ciuleanu TE, et al. A randomized placebo-controlled trial of erlotinib in patients with advanced non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line chemotherapy. A National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) trial. J Clin Oncol 2004; 22:7022.

    Google Scholar 

  70. Tsai C, Chiu C, Chen Y. Gefitinib in patients with advanced non-small cell lung cancer: a relationship between drug toxicity and tumor response. Thoracic Med 2003; 18:93.

    Google Scholar 

  71. Wu MF, Fahn HJ, Wu TC. Experience of gefitinib (Iressa) for previously treated patients with advanced non-small cell lung cancer. Thoracic Med 2003; 18:203.

    Google Scholar 

  72. Chen K, Chang GC, Yang TY. A comparison of gefitinib monotherapy and chemotherapy with cisplatin and gemcitabine in chemonaive patients with advanced non-small cell lung cancer: a case control study. Thoracic Med 2003; 18:218.

    Google Scholar 

  73. Bailey R, Kris M, Wolf M. Gefitinib (‘Iressa’, ZD1839) monotherapy for pre-treated advanced non-small cell lung cancer in IDEAL-1 and 2: tumor response is not clinically relevantly predictable from tumor EGFR membrane staining alone. Lung Cancer 2004; 41:71.

    Article  Google Scholar 

  74. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 2004; 22:3238.

    Article  PubMed  CAS  Google Scholar 

  75. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004; 64:9139.

    Article  PubMed  CAS  Google Scholar 

  76. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129.

    Article  PubMed  CAS  Google Scholar 

  77. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004; 304:1497.

    Article  PubMed  CAS  Google Scholar 

  78. Huang S, Armstrong EA, Benavente S, Harari PM. Dual agent molecular targeting of the EGFR: combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004; 64:8195.

    Google Scholar 

  79. Han SW, Hwang PG, Chung DH, et al. Epidermal growth factor receptor (EGFR) downstream molecules as response predictive markers for gefitinib (Iressa, ZD1839) in chemotherapy-resistant non-small cell lung cancer. Int J Cancer 2005; 113:109.

    Article  PubMed  CAS  Google Scholar 

  80. Lander ES. Array of hope. Nat Genet 1999; 21(1 Suppl):3.

    Article  PubMed  CAS  Google Scholar 

  81. Brennan P. Gene-environment interaction and aetiology of cancer: what does it mean and how can we measure it? Carcinogenesis 2002; 23:381.

    Article  PubMed  CAS  Google Scholar 

  82. Caporaso NE. Why have we failed to find the low penetrance genetic constituents of common cancers? Cancer Epidemiol Biomarkers Prev 2002; 11:1544.

    PubMed  Google Scholar 

  83. Popanda O, Schattenberg T, Phong CT, et al. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 2004; 25:2433.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Clinical Oncology, Royal Marsden Hospital, London, UK

    Tim Benepal, Ying Zee & Tim Eisen

  2. Institute of Cancer Research, Sutton, Surrey, UK

    Athena Matakidou & Richard Houlston

Authors
  1. Tim Benepal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Athena Matakidou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ying Zee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Richard Houlston
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tim Eisen
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Sotiria General Hospital, Athens Medical School, Athens, Greece

    Konstantinos N. Syrigos MD, PhD

  2. Royal Marsden NHS Trust Hospitals, London, UK

    Christopher M. Nutting MB BA, MD, FRCR

  3. Evangelismos General Hospital, Athens Medical School, Athens, Greece

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

  4. Faculty of Medicine, McGill University, Montreal, Canada

    Charis Roussos MD, MSc, PhD, MRS, FRCP(C)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer Berlin Heidelberg

About this chapter

Cite this chapter

Benepal, T., Matakidou, A., Zee, Y., Houlston, R., Eisen, T. (2006). Genetics of Lung Cancer: Current Thinking on Genetic Predisposition to the Disease and Response to Treatment. In: Syrigos, K.N., Nutting, C.M., Roussos, C. (eds) Tumors of the Chest. Springer, Berlin, Heidelberg . https://doi.org/10.1007/3-540-31040-1_5

Download citation

  • DOI: https://doi.org/10.1007/3-540-31040-1_5

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-31039-6

  • Online ISBN: 978-3-540-31040-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation